证券代码：【301392】 证券简称：【汇成真空】 编号：【IR-2025005】 | 投资者关系活动类别 | ☐ 特定对象调研 ☐ 分析师会议 | | | --- | --- | --- | | | ☐ 媒体采访 业绩说明会 | ☐ | | | ☐ 新闻发布会 ☐ 路演活动 | | | | 现场参观 ☐ | | | | 其他（2025年广东辖区投资者集体接待日暨辖区上市公司中报业 | | | | 绩说明会活动） | | | | 通过"全景路演"网站（http://rs.p5w.net）参与2025年广东辖区 | | | 参与单位名称及人员姓名 | 投资者集体接待日暨辖区上市公司中报业绩说明会活动的投资者 | | | 时间 | 2025年9月19日 15:30-17:00 | | | | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 地点 | 采用网络远程的方式召开 | | | | 董事、总经理 李志荣先生 董事、财务负责人 林琳女士 | | | | 独立董事 涂溶先生 | | | 上市公司接待人员姓名 | 独立董事 江绍基先生 | | | | 独立董事 鄢国祥先 ...

广东豪美新材股份有限公司 证券代码：002988 证券简称：豪美新材 1 | | 等汽车零部件企业提供高强度铝挤压合金材料及轻量化 | | --- | --- | | | 汽车底盘件、安全件等，应用终端覆盖奔驰、宝马、丰田、 | | | 本田等一线外资、合资品牌，广汽、长城、吉利等自主车 | | | 企，小鹏、蔚来、赛力斯、小米等汽车品牌，公司是国内 | | | 最具规模的汽车轻量化铝基新材料企业之一。另一方面公 | | | 司也在加大产品研发力度，积极开拓铝合金轻量化材料在 | | | 新兴领域的应用，培育新的增长点。 | | | 2. 请问华东汽车轻量化项目是有确定订单或意向 | | | 么？客户方便透露么？ | | | 答：您好，感谢您对公司的关注与支持。目前，公司 | | | 在安徽芜湖建设的汽车轻量化部件加工基地正在加紧筹 | | | 划和建设中。汽车轻量化业务作为公司重要转型发展方 | | | 向，本项目建成后将增加约3万吨汽车产品加工能力，可 | | | 以实现对华东市场快速响应与交付，满足市场需求，增强 | | | 公司总体竞争力。 | | 关于本次活动是否涉及 | 本次活动不涉及未公开披露的 ...

Group 1: Investor Relations Activity - The investor relations activity was an earnings briefing held on September 19, 2025, from 15:30 to 17:00 via an online platform [2] - Key company representatives included the Chairman and CEO Liu Peng, Board Secretary and Vice President Liang Ge Yu, and CFO Gao Bo [2] Group 2: Share Buyback and Executive Compensation - The share buyback plan is valid until April 1, 2026, and investors are encouraged to monitor announcements regarding its progress [2] - Concerns were raised about executive salaries being above industry standards during economic downturns; the company explained that a compensation committee is in place to align management incentives with long-term corporate goals [3] Group 3: Dividend and Financial Performance - The company disclosed its 2025 semi-annual equity distribution announcement on September 17, 2025, and will comply with legal disclosure obligations for any related matters [3] - The company currently offers a range of core brands and products, including household paper, personal care items, and health products, aiming to meet evolving consumer needs [3] Group 4: Future Outlook - The company is committed to embracing digital market developments and aims to be a companion in enhancing the quality of life for consumers [3] - The company invites investors to visit its headquarters for product experiences and further engagement [3]

Group 1: Investor Relations Activity - The investor relations activity was an earnings briefing held on September 19, 2025, from 15:00 to 17:00 via an online platform [2] - The meeting was attended by key company executives, including Chairman and CEO Wang Zhenglin, CFO Shen Bin, and Secretary of the Board Du Yunbo [2] Group 2: Key Questions and Responses - The company is actively discussing the H-share listing with relevant intermediaries, but specific details have not been finalized [2] - For new tobacco brands, investors were directed to the company's periodic reports for information on market breakthroughs [2] - The first experimental satellite is expected to launch by the end of 2025, subject to external factors [3] - In the first half of 2025, the company reported a revenue of 186 million yuan from aluminum-plated paper products, with normal production conditions [3] - The company acknowledged a market value decrease of over 2 billion yuan in the past month and stated it would manage its market value based on market dynamics and financial arrangements [3]

Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. was established in 2002, focusing on drug research, production, and sales, particularly in pediatric and chronic disease medications [2][3] - The company has a total of 204 drug registration certificates, including 90 national medical insurance varieties and 27 national essential drug varieties [3] Pediatric Drug Segment - Pediatric drug revenue accounted for 61.65% of the pharmaceutical manufacturing business, with a revenue of 357 million CNY in the first half of 2025 [3][4] - The company holds 27 pediatric drug registration certificates and has 16 pediatric drug projects under research, covering diseases such as epilepsy and influenza [4][5] - The company aims to enhance its market share in pediatric drugs by leveraging policy support and increasing public awareness [4] Research and Development - The company has approximately 60 ongoing research projects, including 14 innovative drug projects and 28 products pending approval [3] - The innovative drug AR882 has shown promising results in clinical trials, with all global Phase III clinical trial enrollments completed by August 2025 [5][6] Financial Performance - The company experienced a decline in revenue and net profit in the first half of 2025, attributed to industry conditions and internal business adjustments [6] - The company implemented stock incentive plans to motivate employees and enhance performance, granting over 5 million shares to 160 employees [6] Marketing and Sales Strategy - The company is focusing on expanding its marketing network across 31 provincial regions in China and enhancing its presence in new retail channels [7][8] - New product registrations are expected to positively impact sales, with 14 new drug registration certificates obtained in 2025 [6][7] Raw Material Production - The company has established a raw material drug base, which is expected to reduce costs and improve self-sufficiency in raw materials [9] - Currently, the company has 10 registered raw material drug numbers and 4 projects under research [9]

Group 1: Company Overview and Financial Performance - The company is a high-tech enterprise engaged in the R&D, production, and sales of stage lighting equipment, architectural lighting equipment, and truss equipment [2] - In the first half of 2025, the company increased R&D investment and integrated with Danish SGM company, leading to a new headquarters being put into use [2] - The company reported a revenue of approximately RMB 522 million, a year-on-year decrease of about 21.99% [2] - The net profit attributable to the parent company was approximately RMB 78 million, a year-on-year decrease of about 61.69% [2] Group 2: Business Structure and Market Performance - The company's business model is driven by "ODM + OBM," with overseas sales accounting for approximately 94% and domestic sales for about 6% in the first half of 2025 [4] - The U.S. market has been significantly impacted by changes in the trade environment, while demand in other overseas regions remains stable [4] - The domestic market faces intensified competition due to international trade environment changes, but there are signs of recovery in the U.S. market [4] Group 3: Product Development and Market Outlook - The penetration rate of new products continues to rise, with sales revenue from new products increasing year-on-year despite overall revenue decline [5] - The company aims to enhance R&D capabilities and introduce competitive products to increase market share [6] - According to Live Nation's Q2 report, overseas performance events are expected to grow steadily over the next two years, indicating a favorable market outlook [6] Group 4: Strategic Adjustments and Future Plans - The company is adjusting its product structure and enhancing R&D innovation to respond to future market challenges and opportunities [7] - With the stabilization of the U.S. trade environment, the company is optimistic about the recovery of the U.S. market [7]

Group 1: Company Performance and Market Response - The company's stock price has remained below the issue price for three years, raising concerns among management about market performance and value management strategies [2][3] - Management emphasizes that stock performance is influenced by various factors, including macroeconomic conditions, investor preferences, market expectations, and overall capital market environment [2] - The company has implemented several market value management measures, including equity incentives, share buybacks, and cash dividends [3] Group 2: Business Strategy and Growth Opportunities - The company continues to focus on its core business while actively responding to market changes and enhancing its competitive advantages [3] - There is an ongoing effort to explore new application areas for hot melt adhesive products, aiming to identify potential second growth lines and opportunities [3] - The goal is to transform the company into a comprehensive adhesive manufacturer, thereby creating sustained value and returning profits to shareholders [3]

Group 1: Export Strategy and Market Expansion - The company has a global export business, primarily focusing on ODM/OEM orders, with exports accounting for approximately 75% of total sales [3] - Plans for self-owned brand expansion in emerging markets are currently in the trial phase, with a small scale of operations [2] - The company aims to enhance domestic market penetration through innovation-driven strategies, with a focus on launching new products in the second half of 2025 [3] Group 2: Research and Development Investments - The company invested nearly 270 million in R&D in the first half of the year, focusing on various product categories including kitchen appliances and personal care products [4] - A new appliance research institute was established in 2024 to bolster R&D efforts and product innovation [3] - Continuous investment in R&D is expected to yield new product series that meet market demands, particularly in smart and personalized small appliances [4] Group 3: Financial Health and Risk Management - The company's asset-liability ratio was 46.31% at the end of 2024 and decreased to 44.73% by mid-2025, indicating a reasonable financial structure [4] - Strategies to mitigate foreign exchange risks include the use of foreign exchange derivatives and timely settlement arrangements [4] - The company is focused on optimizing its capital structure and may consider equity financing to improve financial stability [4] Group 4: Product Innovation and Market Trends - The company is committed to enhancing product innovation across various categories, including commercial machines and smart gardening tools [3] - Future product launches will include innovations that cater to the growing demand for smart home and IoT products [4] - Collaboration with new consumer sectors is being explored to meet personalized demands in small appliances [6]

Group 1: Financial Performance - The company achieved a revenue of 236 million CNY in the first half of 2025, representing a year-on-year increase of 18.64% [1] - The net profit attributable to shareholders was 33.80 million CNY, up 28.26% compared to the previous year [1] - As of June 30, 2025, total assets amounted to 1.872 billion CNY, with net assets attributable to shareholders at 1.619 billion CNY [1] Group 2: Strategic Goals - The company emphasizes research and development, aiming to drive growth through innovation while optimizing production capacity based on order conditions [1] - The company’s products are primarily used in military applications, with a small proportion of revenue coming from civilian products [2] - The company balances shareholder returns with future growth investments by focusing on continuous R&D, market expansion, and potential acquisitions [2]

Group 1: Company Strategy and Performance - The company emphasizes strategies to boost stock prices and performance through enhanced operational capabilities and market confidence [2] - Two share repurchase plans have been launched to support stock price stability and investor confidence [2] - The company aims to improve customer service and market competitiveness through both organic growth and external acquisitions [2] Group 2: Product Development and Market Recognition - The company has significantly increased its product offerings in the antibody and recombinant protein sectors, with over 4,200 products developed at the Hangzhou center and over 1,800 at the Nanjing center as of mid-2025 [3] - Self-owned brand products have achieved over 20% growth compared to the previous year, with an increasing revenue share from these brands [3] Group 3: Financial Performance and Challenges - In the first half of 2025, the company reported a revenue of 1.5 billion, maintaining a similar level to 2024, but faced a net profit loss due to market demand issues and increased competition [3] - The company’s gross margin has been under pressure, and while self-owned brands are growing rapidly, their overall revenue contribution remains low, delaying significant improvements in overall profitability [3] - The company is closely monitoring stock price fluctuations and plans to continue share repurchase activities in response to market conditions [3]